Mallinckrodt sees Q1 adjusted EPS ex-items $6.00-$6.50, consensus $7.14
Driven by its ongoing transformation, Mallinckrodt will prospectively classify the "Specialty Generics Disposal Group" as discontinued operations, which includes the Specialty Generics segment3, certain non-promoted branded products within the Specialty Brands segment, and the company's ongoing post-divestiture supply agreement. Beginning in the Q1, the historical financial results attributable to the Specialty Generics Disposal Group will be reflected in the consolidated financial statements as discontinued operations. Mallinckrodt seeks to dispose of these products to further its strategic evolution to being a brands-focused innovation-driven specialty pharmaceutical growth company. Mallinckrodt's guidance for 2018 is provided exclusive of the aforementioned businesses. Sees FY18 total net sales for continuing operations up 3%-6%; net interest expense $370M-$390M; adjusted effective tax rate 9%-11%.